AttgeNO
Sweden - SolnaBiotechnology
Focus: AttgeNO is a Swedish public biotech specializing in nitric oxide-donating drugs for cardiovascular disease, currently in early-stage clinical development with a focused pipeline in pulmonary hypertension.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About AttgeNO
AI assessmentNot HiringNo open roles listed right now. Follow AttgeNO to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
The Prevalence of Pulmonary Hypertension in Patients With COVID-19.
Hypertension, PulmonaryClinical Trials (1)
NCT04459364The Prevalence of Pulmonary Hypertension in Patients With COVID-19.
N/AHelp build intelligence for AttgeNO
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.